Satralizumab monotherapy effective for seropositive NMOSD
- Posted on: Jul 1 2020
- Leave a response
This phase 3 study assessed the safety and efficacy of satralizumab monotherapy for neuromyelitis optica spectrum disorder (NMOSD).
Source: AAO
Posted in: Uncategorized